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journal homepage: www.elsevier .com/locate / t r ivac3PH, UK.arthralgia. Of all systemic adverse events in the combined mid-dose group, 96% were mild, 3% were mod-
erate and 1% were severe (but none of these were judged to be vaccine-related). Pre-vaccination myco-
bacterial exposure did not affect the adverse event profile. The size of local reaction and frequency of
systemic adverse events increased with MVA85A vaccine dose. There were no documented fevers in
the low-dose group, whilst 3% of subjects in the combined mid-dose group and 21% in the high-dose
group had documented fevers. Peak local reactions were larger after a second poxvirus vaccination,
but other local and systemic adverse events were comparable to a single MVA85A vaccination. No severe
systemic AEs or serious adverse events in any group were judged to be vaccine-related. Local AEs com-
pared favourably to BCG vaccine-induced local AE and systemic AEs after MVA85A vaccination were com-
parable to those after the live viral Yellow Fever vaccine in similar populations. There were no
correlations found between local reaction size or body temperature and adaptive immune responses
(measured by ex vivo interferon gamma Enzyme Linked Immunospot).
Conclusions: The candidate TB vaccine, MVA85A has been safely administered to over 100 healthy adults
in the UK. Intradermal vaccination with MVA85A induced a transient, superficial reaction local to the
injection site and mild short-lived viral symptoms. The local and systemic AE profile of MVA85A vacci-
nation was comparable to published data of other intradermal vaccines and live viral vaccines respec-Article history:
Received 11 May 2012
Revised 11 July 2012
Accepted 16 July 2012
Keywords:
Tuberculosis
Vaccine
MVA85A
Safety
Reactogenicity1879-4378/$ - see front matter  2012 Elsevier Ltd. A
http://dx.doi.org/10.1016/j.trivac.2012.07.001y of the candidate TB vaccine, MVA85A compared
r vaccines, and correlation between MVA85A
cellular immunogenicity
ttain a, Ian D Poulton a, Angela M Minassian a, Clare Sander a,
b, Iman Satti a, Ansar A Pathan a,1, Alison M Lawrie a,
ng, Oxford University, Roosevelt Drive, Oxford OX3 7DQ, UK
xe, University of Oxford, Linton Road, Oxford OX2 6UD, UK
a b s t r a c t
Background: The development of a new, more effective vaccine against tuberculosis (TB) for use in
healthy and HIV-infected adults, children and infants, remains a global health priority. MVA85A is a can-
didate tuberculosis vaccine designed to enhance immunity to the existing vaccine, Bacillus Calmette-
Guerin (BCG). MVA85A entered clinical trials in 2002 and has now progressed to Phase IIb proof-of-con-
cept efficacy trials in infants and HIV-infected adults in Africa.
Methods: A detailed analysis was conducted of the cumulative safety data of intradermal delivery of
MVA85A in 112 healthy adult subjects in a series of open label, single arm, non-controlled, Phase I safety
and immunogenicity clinical trials in the UK. The trials differed with respect to previous mycobacterial
exposure, vaccine regime and dose. Objective safety measures (local reaction size and body temperature)
were evaluated for correlations with adaptive antigen-specific immune responses.
Results: All subjects in the combined mid-dose group developed a local reaction, of which 92% were mild,
8% were moderate and no reactions were severe. Around 90% of subjects in each group reported at least
one systemic adverse event, most commonly headache, myalgia, malaise, feeling feverish, fatigue andll rights reserved.
1. Introduction
Tuberculosis (TB) is one of the leading global causes of death
and disability from a single infectious agent, Mycobacterium tuber-
culosis (M.tb), with an estimated 8.8 million new infections and 1.5
million deaths in 2010 [1]. The Stop TB Partnership goals include
reducing the global burden of TB (prevalence and death rates) by
50% by 2015 compared to 1990 levels and eliminating TB as a pub-
lic health problem by 2050. Prophylactic immunization is a key
strategy in reducing the incidence of TB.Mycobacterium bovis Bacil-
lus Calmette-Guerin (BCG), the only licensed TB vaccine, is given in
mass immunisation campaigns to neonates in high-risk popula-
tions as part of the WHO Expanded Programme on Immunisation
2.2. Location
The trials were conducted at the Centre for Clinical Vaccinology
and Tropical Medicine, Churchill Hospital, Oxford and were spon-
sored by the University of Oxford. Northwick Park Hospital, London
was used as a second site for recruitment and follow up ofM.tb-in-
fected subjects [7].
2.3. Subjects
Healthy adult subjects between the ages of 18 and 55 years
were recruited from the Oxford region and, for latently M.tb-in-
fected (LTBI) subjects, from TB contact clinics in Oxford and London
sion; clinically significant past or current medical history; psychi-
[18]. Clinical grade MVA85A (batch number 010402) was manufac-
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inated TB in children but its efficacy wanes with time [2–4]. In
addition, BCG affords highly variable protection against pulmonary
disease, which accounts for the burden of global TB mortality and
morbidity [5]. A new, more effective TB vaccine is a major global
health priority. A feasible and promising strategy is for a new pro-
phylactic vaccine to be given in a regime which includes BCG, in or-
der to enhance the immunity afforded by BCG.
We are developing a subunit viral-vectored vaccine, using Mod-
ified Vaccinia Virus Ankara (MVA) as a delivery system for the
mycobacterial antigen 85A. This candidate vaccine is designated
MVA85A and has been evaluated in a series of small Phase I safety
and immunogenicity clinical trials in the UK since 2002 [6–9]. The
promising safety and immunogenicity of MVA85A led to further
clinical trials in target populations in South Africa, The Gambia
and Senegal [10–15]. Two proof-of-concept (Phase IIb) efficacy tri-
als are now underway in BCG-vaccinated South African infants and
HIV-infected African adults. As the early UK trials had small group
sizes (typically 12 subjects), only very common adverse events
(AEs) were detected by individual trials. Now that over 100 healthy
adult subjects in the UK have received MVA85A vaccination, we
have the opportunity to perform an integrated further evaluation
of the cumulative safety and tolerability of MVA85A vaccination
in a larger cohort.
2. Subjects and methods
2.1. Clinical trials
Safety data from seven open label, single arm, non-controlled
safety clinical trials were analysed (Table 1) [7–9,16,17] (Porter,
unpublished data). The trial protocols all received full ethical ap-
proval from the Oxfordshire Research Ethics Committee (OXREC)
or the Gene Therapy Advisory Committee. Regulatory approval
for these studies was granted by the Medicines and Healthcare
products Regulatory Agency (MHRA), UK.
Table 1
Demographics of subjects vaccinated with MVA85A in the UK according to group.
Group Vaccine dose (pfu) N Males (%) Median ag
Ma 5.0  107 14 5 (36) 29 (19–54
MMb 5.0  107 11a 5 (45) 31 (20–48
BMc low-dose 1.0  107 12 4 (33) 27 (21–42
BM mid-dose 5.0  107 43 17 (40) 26 (23–54
BM high-dose 1.0  108 24 11 (46) 24 (19–32
LTBId 5.0  107 12 10 (83) 31 (20–49
BFMe 5.0  107 7 3 (43) 30 (24–47
a M = single vaccination with MVA85A.
b MM = Two sequential vaccinations with MVA85A (of the 14 subjects vaccinated
4 weeks within the same clinical trial).
c BM = single vaccination with MVA85A in previously BCG-vaccinated subjects.
d LTBI = Latent M.tb infection (10 of the 12 subjects had evidence of prior BCG vaccin
e BFM = Sequential vaccination with FP85A, followed by MVA85A after an interval ofNCT00465465 [17]
NCT00427453 [8] NCT00427830 [9] NCT00653770 [16]
NCT00465465 [17] NCT00548444 (Porter, unpublished data)
NCT00456183 [7]
NCT00653770 [16]
h MVA85A, 11 subjects received a second MVA85A vaccination after an interval oftured to Good Manufacturing Practice standard by IDT Biologika
GmbH (Dessau, Germany). MVA85A was administered by intrader-
mal injection into the deltoid area of the arm on the day of vacci-
nation at doses of 1  107 plaque forming units (pfu) (low-dose);
5  107 pfu (mid-dose) or 1  108 pfu (high-dose) (Table 1). The
low and mid-dose vaccinations were administered as a single
intradermal injection. The high-dose vaccinations were adminis-
tered as two injections, each a dose of 5  107 pfu, delivered simul-
taneously one into each arm.
2.5. Enrolment and follow up
Subjects received their first MVA85A vaccination on the day of
enrolment and were followed up for 24 or 52 weeks following
vaccination, depending on the individual trial protocol.
ange) (years) Clinicaltrials.gov reference and citationatric disorders; injecting drug use or excess alcohol use; confirmed
or planned pregnancy; and any previous MVA or Fowlpox (FP9)
vaccinations. Subjects with clinically significant abnormalities in
their routine haematology, biochemistry or urinalysis results, or
infection with human immunodeficiency virus (HIV), hepatitis B
virus (HBV) or hepatitis C virus (HCV) were also excluded.
Subjects were required to consent to refrain from blood donation
throughout the trials and females were required to use continuous
effective contraception.
2.4. MVA85A
The construction of MVA85A has been described previously[7]. Fully informed written consent was obtained from all subjects
prior to any study procedures being performed. Before enrolment,
all subjects underwent medical screening, which included medical
history, physical examination, urinalysis and blood tests. Specific
exclusion criteria included significant allergy; immunosuppres-ation).
4 weeks in previously BCG-vaccinated subjects.
trial); ‘‘BCG’’ (limits: meta-analysis); ‘‘BCG’’ (limits: review);
‘‘Yellow Fever vaccine AND humans’’ (limits: clinical trial); ‘‘Yellow
Fever vaccine AND systematic review’’ and ‘‘Yellow Fever vaccine’’
(limits: humans, meta-analysis).
2.10. Statistical analysis
The analysis of AE frequencies was descriptive. For statistical
analysis of objective measures (local reaction diameter and body
temperature), non-parametric tests were used as the data were
not normally distributed. The diameters of local reactions between
groups were compared using the Mann Whitney U test (Stata 9).
The Wilcoxon signed rank test for paired data were used to com-
pare diameters of sequential vaccinations within a group (Stata
9). The Spearman test for non-parametric data were used to test
for correlations between peak IFNc ELISpot responses to 85A and
both local reaction diameters and peak recorded temperatures
(Stata 9).
3. Results
3.1. Subjects
Safety data from all healthy subjects in the UK who had re-
ceived an MVA85A vaccination were evaluated (Fig. 1). There were
more females than males and the median age of enrolled subjects
was similar between genders (Fig. 1). There were fewer females
Vaccinology 1 (2012) 27–35 292.6. Groups
Subjects were grouped according to their previous exposure to
mycobacteria, vaccination regime and vaccine dose. The mid-dose
vaccination groups are named M, MM, BM, LTBI and BFM and con-
sisted of 76 subjects who received a total of 87 vaccinations with
MVA85A. The mycobacterially naïve M group (n = 14) had received
no prior BCG vaccination and had negative tuberculin skin test pre-
vaccination before vaccination with MVA85A. The MM groups
were 11 of the 14 mycobacterially naïve subjects who received a
second MVA85A vaccination. The BM group (n = 43) had no evi-
dence of LTBI but had received prior BCG vaccination. Ten subjects
in the LTBI group (n = 12) had evidence of prior BCG vaccination.
The BFM group (n = 7) had been previously BCG-vaccinated and
were vaccinated with another candidate TB vaccine (FP85A)
4 weeks prior to MVA85A. The low-dose group (n = 12) and high-
dose groups (n = 24) had all been BCG-vaccinated prior to enrol-
ment and each received one MVA85A vaccination.
2.7. Safety evaluation
The safety profile of the vaccine was evaluated by active and
passive AE collection for the duration of follow up. Clinically qual-
ified investigators conducted all screening, vaccination and follow-
up visits. Subjects were given a diary card to complete for the first
7 days following immunisation. At regular follow up appointments,
the vaccine injection site was reviewed, and solicited and unsolic-
ited AEs were recorded by the investigators (Supplementary data,
Table S1). Blood samples for routine haematology and biochemis-
try were taken before and after vaccination. At the time of this
analysis, all AEs were assigned grades for causality and severity
(Supplementary data, Table S1). For maximum stringency, all solic-
ited AEs reported with a reasonable temporal relationship to the
vaccine were recorded as vaccine-related and any AE designated
as possibly, probably or definitely related to MVA85A vaccination
were evaluated as vaccine-related AEs. Unrelated AEs were also
analysed. Documented fever was defined as body temperature
greater than 38.0 C. An AE was defined as serious if it was life
threatening, caused persistent or significant disability or incapac-
ity, or resulted in admission to hospital.
2.8. Immunological evaluation
Ex vivo interferon gamma (IFNc) Enzyme Linked ImmunoSor-
bent (ELISpot) assays were the main readout of vaccine immunoge-
nicity and were performed on blood taken prior to and 1 week after
vaccination and at regular time points during the follow up period
as previously described [7–9]. Cryopreserved peripheral blood
mononuclear cells (PBMC) and serum were stored and used after
trials ended to comprehensively characterise vaccine-induced
immunogenicity [19,20].
2.9. Literature reviews
As the early clinical trials of MVA85A did not include control
groups, the reactogenicity of two licensed vaccines, BCG and a
Yellow Fever vaccine, were summarised in order to provide
comparative data for MVA85A. BCG is the only vaccine currently
licensed for immunisation against TB and is administered intrader-
mally. Yellow Fever vaccine is a live viral vaccine, which is widely
used for immunisation of adults and is administered subcutane-
ously or intradermally. An electronic database (medline) was
searched for systematic reviews, meta-analyses and prospective
R. Rowland et al. / Trials inclinical trials recruiting healthy adult subjects in Europe or North
America. The following search terms were entered into medline:
‘‘BCG vaccine AND humans AND tuberculosis’’ (limits: clinicalthan males in the LTBI group, but more females than males in all
other groups (Table 1).
3.2. Adverse events
3.2.1. Local reactions
For the mid-dose MVA85A vaccinations, the profiles of AEs local
to the injection site were similar for groups M, MM and BM, with
Screened for inclusion in a clinical trial for healthy 
adult subjects in the UK  n=182 
Excluded from participation n=58  
did not meet inclusion criteria 
n=49 
withdrew before enrolment n=8 
eligible but not required n=1 
Enrolled in a clinical trial n=124 
Not vaccinated with MVA85A 
n=12 
Lost to follow up n=0 
Included in MVA85A safety analysis n=112 
Males 50 (45%) 
Median age (range) 27 years (19-54)Fig. 1. Subjects shows the flow of subjects from screening for the individual clinical
trials to inclusion in this analysis.
respect to local AE frequency and severity (Fig. 2). Based on a com-
bined analysis of local AEs in all 69 subjects in the mid-dose M, BM
and LTBI groups, all subjects developed injection site erythema and
swelling, and most subjects also reported local scaling, pain and
pruritus (Fig. 2, Table 2). Of all 330 local AEs, 92% (62) were mild,
8% (27) were moderate and none were severe. Injection site ery-
thema, swelling and warmth developed on the day of vaccination,
followed by pain, pruritus and scaling (Table 3). Pain, pruritus and
warmth were present for a few days in most cases; scaling and
swelling for a few weeks; and erythema for 3–4 months (Table 3).
Unsolicited local AEs reported were injection site ooze (3/330, 1%),
rash (2/330, 0.6%), scar (1/330, 0.3%), limitation (1/330, 0.6%) and
localised muscular pain (2/330, 0.6%) and all were mild.
Severe erythema or swelling were reported for three subjects in
the MM group and five subjects in the BFM group, but no subjects
in the other groups had severe local reactions (Fig. 2). Severity clas-
sifications of erythema and swelling were based on measurements
of the diameters. Peak (days 1 and 2) diameters of local erythema
recorded in subject diary cards were larger after MVA85A vaccina-
tion in the BFM group compared to the BM group (Fig. 3, Table 4).
After a second vaccination with MVA85A (group MM), peak (days 1
and 2) diameters of erythema were larger compared to the peak
diameters recorded after the first vaccination in the same subjects
(group M) (Fig. 3, Table 4). Diameters of swelling were also larger
after the second vaccination (MM) compared to the first vaccina-
tion (M) (data not shown).
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30 R. Rowland et al. / Trials in Vaccinology 1 (2012) 27–35Fig. 2. AE frequency and severity after MVA85A vaccination. Severity and frequency
5  107 pfu (mid-dose) of MVA85A vaccination. Naïve M = first MVA85A vaccination
vaccination (5  107 pfu) in mycobacterially naïve subjects (n = 11); BM = single
LTBI = single MVA85A vaccination (5  107 pfu) in LTBI subjects (n = 12, 10 were pre
BCG-vaccinated subjects, vaccinated with candidate TB vaccine FP85A 4 weeks prior (n
(5  107 pfu; groups M, BM, LTBI; n = 69); Bars are subdivided according to severity: grethe most frequently reported local and systemic AEs following immunisation with
 107 pfu) in mycobacterially naïve subjects (n = 14); naïve MM = second MVA85A
A85A vaccination (5  107 pfu) in previously BCG-vaccinated subjects (n = 43);
sly BCG-vaccinated); BFM = single MVA85A vaccination (5  107 pfu) in previously
= 7); mid-dose (combined) = all subjects receiving single vaccination with MVA85A
y = mild; white = moderate; black = severe.
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Local erythema 100% (69) 100% (14) 88% (15)
8% (
ew c
% (0
VacLocal pain 65% (45) 100% (14) 65% (11)
Local pruritus 84% (58) 64% (9)
Local swelling 100% (69) 100% (14) 88% (15)
Local ulcer 100% (17) 100% (20) 9
Axillary lymph nodes 6% (4) 14% (2) f
Arthralgia 23% (16) 29% (4)
Asthenia/fatigue 26% (18)
Feverb 3% (2) 0% (0) 0
Feverishc 33% (23) 14% (2)
GI event
Headache 51% (35) 36% (5)
Malaise 41% (28)
Myalgia 46% (32) 36% (5)Table 2
AE profiles of Yellow Fever and BCG vaccines. Frequency of AEs in the combined mid-d
data are the percentage of subjects reporting each AE, with the number of subjects in
Vaccine MVA85A BCG BCG BCG B
Route id id id id id
Study dbRCTa R
Source [21] [22] [24] [
N 69 14 17 20 4
R. Rowland et al. / Trials inThe frequencies of local AEs in the low and high-dose groups
were similar to those in the combined mid-dose group, except
injection site pain was more frequent in the high-dose group
(96%, 23/24) than the low-dose group (50%, 6/12) (data not shown)
[17]. There was one report of severe swelling in the low-dose group
and one report of severe pain in the high-dose group [17]. Peak
(days 1 and 2) erythema diameters from subject diary cards were
larger at high-dose compared to mid- and low-doses (Fig. 3,
Table 4). Peak diameters of swelling were similar between the
three doses (data not shown).
3.3. Systemic AEs
The frequencies and severities of systemic AEs were similar be-
tween the mid-dose groups, except a smaller proportion of sub-
jects in the MM group (7/11, 64%) reported any systemic AE,
compared to the other groups (M 93%, 13/14; BM 86%, 37/43; LTBI
92% 11/12; BFM 86%, 6/7) (Fig. 2).
In the combined analysis of a single mid-dose vaccination of
MVA85A (groups M, BM and LTBI), the most commonly reported
systemic AEs which were deemed possibly, probably or definitely
Nausea or vomiting 12% (8) 7% (1)
a db = Double blind, RCT = randomised controlled trial.
b Fever = documented fever.
c Feverish = symptoms in the absence of documented fever.
Table 3
AE onset and duration. The median day of onset and duration of possibly, probably or
definitely vaccine-related AE in the combined mid-dose group are displayed.
Minimum and maximum results are in parentheses.
Adverse event Median day of onset
(range)
Median duration, days
(range)
Systemic Arthralgia 1 (0–5) 2 (1–3)
Documented
fever
1 (0–4) 1 (1–3)
Fatigue 1 (0–6) 2 (1–5)
Feverish 1 (0–5) 2 (1–3)
Headache 1 (0–6) 1 (1–5)
Malaise 1 (0–6) 1 (1–7)
Myalgia 1 (0–6) 2 (1–6)
Injection
site
Erythema 0 (0–7) 106 (1–203)
Pain 1 (0–14) 3 (1–9)
Pruritus 4 (0–28) 2 (1–25)
Scaling 7 (0–28) 8 (1–171)
Swelling 0 (0–7) 15 (1–171)
Warmth 0 (0–6) 4 (1–14)related to vaccination were headache, myalgia, malaise, feeling
feverish, fatigue and arthralgia (Fig. 2, Table 2). Vaccine-related
systemic AEs reported less frequently were nausea (8/69, 12% sub-
jects), documented fever (5/69, 7%) and axillary lymphadenopathy
(4/69, 6%). Vasovagal symptoms, dizziness and diarrhoea were
infrequently reported (1% of AEs). Upper respiratory tract infec-
tions comprised 8% of all systemic AEs reported (included unre-
lated AEs) but none were deemed definitely or probably related
to MVA85A vaccination (Supplementary data, Table S2). MVA85A
vaccine-related systemic AEs developed a median of 1 day after
vaccination and resolved after a median of 1 day (Table 3). Of all
293 systemic AEs, 281 (96%) were mild; nine (3%) were moderate
and three AEs (1%) were severe (Supplementary data, Table S2).
The three AEs classified as severe were all serious adverse events,
of MVA85A and from published data of BCG and Yellow Fever vaccines. The displayed
entheses.
BCG YF YF YF YF YF
id id sc sc sc sc
RCT RCT RCT dbRCT RCT dbRCT
[25] [29] [29] [27] [28] [26]
29 77 78 659 76 106
97% (28) 82% (63) 32% (25) 30% (198) 18% (14) 5% (5)
90% (26) 8% (6) 19% (15) 42% (274) 24% (18) 9% (10)
68% (52) 12% (9) 21% (139) 16% (12) 0% (0)
47) 83% (24)
ases 5% (4)
9% (7) 1% (1)
30% (197) 20% (15) 8% (8)
) 5% (4) 8 (10) 16% (102) 8% (6) 0% (0)
5% (32) 13% (10) 5% (5)
32% (210) 39% (30) 12% (13)
19% (123)
16% (12) 22% (27) 26% (171) 10% (8) 8% (9)
3% (21)
cinology 1 (2012) 27–35 31but none were deemed MVA85A vaccine-related. These were a
fractured ankle 9 days after vaccination requiring hospitalisation
(BCG-primed group), pregnancy diagnosed 6 weeks after vaccina-
tion (mycobacterially naïve group) and a drug overdose 11 months
after vaccination (LTBI group). There were three moderate vaccine-
related AEs (vasovagal faint, headache and muscle aches), all re-
ported by one subject in the mycobacterially naïve group.
The profile of systemic AEs was similar for the low and high-
dose groups, although the frequencies of vaccine-related systemic
AE increased with dose. The proportion of subjects with any sys-
temic AE in the low-dose group was 42% (5/12); 88% (61/69) in
the combined mid-dose group and 100% (24/24) in the high-dose
group. Similarly, there were no documented fevers in the low-dose
groups, whilst 3% (2/69) of subjects in the combined mid-dose
group and 21% (5/24) subjects in the high-dose group had docu-
mented fevers.
3.4. AEs after BCG and Yellow Fever vaccines: Literature review
No systematic reviews or meta-analysis that included an evalu-
ation of the reactogenicity of BCG or Yellow Fever vaccines in
healthy adult subjects were identified. The search for clinical trials
of intradermal BCG vaccination in healthy adults in Europe and
North America yielded 211 manuscripts, of which seven met the
eligibility criteria for inclusion [21–25]. BCG vaccination was
associated with injection site erythema, swelling, pain and
ulceration (Table 2). Systemic AEs (headache, lymphadenopathy,
Vac32 R. Rowland et al. / Trials inand myalgia) were reported in one single arm study in 14 subjects
conducted by our research group (Table 2) [21].
Fig. 3. Diameter of local reactions following vaccination with MVA85A. Individual measu
following vaccination (where day zero is the day of vaccination). Median diameters for
mycobacterially naïve subjects (n = 14); MM = second MVA85A vaccination (5  107 p
(5  107 pfu) in previously BCG-vaccinated subjects (n = 43); LTBI = single MVA85A vacc
BFM = single MVA85A vaccination (5  107 pfu) in previously BCG-vaccinated subjects, v
MVA85A vaccination (1  107 pfu) in previously BCG-vaccinated subjects (n = 12);
(5  107 pfu; groups M, BM, LTBI; n = 69); high-dose = MVA85A vaccination (1  108 pfu
Table 4
Statistical analysis of diameter of erythema. Peak diameter of erythema (days 1
between groups.
Median diameter (range) Difference in m
BFM 48 mm (4–110)
BM 20 mm (0–90) 25 mm (12–37)
High-dose 26 mm (0–85)
Mid-dose 19 mm (2–90) 8 mm (5–11)
Low-dose 12 mm (6–55) 4 mm (1–8)
MM 30 mm (5–100) Median differen
11 mm (20–8M 18 mm (10–70)cinology 1 (2012) 27–35The search for Yellow Fever vaccine clinical trials in healthy
adults in Europe and North America yielded 54 manuscripts, of
rements of diameter of local erythema recorded by subjects in diary cards for 7 days
each day are connected with lines. M = first MVA85A vaccination (5  107 pfu) in
fu) in mycobacterially naïve subjects (n = 11); BM = single MVA85A vaccination
ination (5  107 pfu) in LTBI subjects (n = 12, 10 were previously BCG-vaccinated);
accinated with candidate TB vaccine FP85A 4 weeks prior (n = 7); low-dose = single
mid-dose (combined) = all subjects receiving single vaccination with MVA85A
) in previously BCG-vaccinated subjects (n = 24).
and 2) from measurements recorded in subject diary cards were compared
edians (95% confidence interval) Mann Whitney U test
p = 0.0001
p = 0.0000
p = 0.045
ce (range):
5)
Wilcoxon sign rank test:
p = 0.004
trials were plotted against peak diameter of erythema for the
same subjects (clinical trials.gov identifiers NCT00423566;
A combined mid-dose analysis was performed for subjects
receiving a single vaccination of 5  107 pfu MVA85A. The AE pro-
with documented fever in 3% of subjects. There were no severe
systemic vaccine-related AEs.
As previously described, there was a lower frequency of pain in
the low-dose group compared to the high-dose group and systemic
AEs were more frequent in the high-dose groups [17]. A dose effect
was also seen with objective measures of AEs. The diameter of local
erythema increased with vaccine dose and 21% of subjects reported
documented fever in the high-dose group compared to 3% in the
combined mid-dose groups and none in the low-dose group. When
MVA85A was the second poxvirus vaccination (MM and BFM
groups), the peak diameter of erythema (and swelling in the MM
group) was larger compared to a single vaccination with MVA85A.
This effect was more marked in the BFM group, in which the peak
diameter of swelling was classified as moderate or severe in all se-
ven subjects and in five of the seven subjects for erythema. How-
ever, group sizes were small, the diameters of reactions were
only larger on days 1 and 2, and frequency and severity of other
local AEs and systemic AEs were similar to those in the other
mid-dose groups.
Since these trials did not include a placebo or vaccination con-
trol group, tolerability was compared to published data of two li-
Fig. 4. Correlation between peak immunogenicity and adverse events. (4a) Peak
recorded body temperature and the peak IFNc ELISpot responses (1 week after
vaccination) for 12 subjects who had received the highest dose (1  108 pfu) of
MVA85A vaccine (Spearman rho = 0.21, p = 0.51). (4b) Peak diameter of erythema
recorded and peak IFNc ELISpot responses (1 week after vaccination) for 104
subjects (Spearman rho = 0.14, p = 0.17).
Vacfile after MVA85A vaccination was similar between mycobacterial-
ly naïve, previously BCG-vaccinated and LTBI subjects, in terms of
AE nature, frequency, severity and duration. All subjects developed
local erythema and swelling, which were associated with tender-
ness, pruritus and scaling in over two thirds of subjects 1–2 days
after vaccination. Warmth and pain, markers of the acute inflam-
matory process, were present for a median of 3–4 days. Erythema
resolved over 3–6 months, but this term simply describes any red-NCT00653770; NCT00465465; NCT00456183; NCT00427830;
NCT00427453); [7–9,16,17]. The median peak diameter of ery-
thema was 22.5 mm (range 0–180 mm). IFNc ELISpot responses
to antigen 85A peaked 1 week after vaccination (median 2309,
range 0–11,066 spot forming cells). There was no correlation be-
tween peak ex vivo IFNc ELISpot responses to antigen 85A and peak
diameter of erythema (Fig. 4B).
4. Discussion
A combined safety evaluation of the candidate TB vaccine,
MVA85A from a series of small, non-controlled, clinical trials in
adults in the UK has been presented. Vaccination safety and immu-
nogenicity has been evaluated in the context of increasing myco-
bacterial exposure; different vaccine doses; and homologous or
heterologous prime with MVA85A or another poxvirus vaccine.
Since biomarkers of protection against M.tb have not yet been
identified, large clinical trials in TB endemic areas are currently
the only means for testing TB vaccine efficacy in humans. The aims
of these early studies were to quickly identify any safety concerns
and demonstrate immunogenicity, in order to provide a platform
for performing efficacy clinical trials. In view of this and the re-
sources available, no vaccination or placebo control groups were
included.which four met the eligibility criteria for inclusion [26–29]. Yellow
Fever vaccine was administered intradermally to healthy adults in
one randomised controlled trial (RCT) and subcutaneously in four
RCTs. Injection site erythema, swelling and pain were more fre-
quent after intradermal than subcutaneous injections in one RCT
comparing the two routes (Table 2) [29]. Systemic AEs after Yellow
Fever vaccination were headache, myalgia, fatigue, malaise, GI
events, fever and arthralgia (Table 2).
3.5. Correlation of immune responses with adverse events
Peak ex vivo IFNc ELISpot responses to a single pool of 15mer
antigen 85A peptides after high-dose vaccination with MVA85A
in 12 subjects (clinical trials.gov identifier NCT00465465) were
plotted against peak body temperatures for the same subjects. IFNc
responses to antigen 85A were detected in all 12 subjects and
peaked 1 week after vaccination (median 6493, range 3030–8409
spot forming cells) [17]. Peak documented body temperature was
in the range 40.0–40.4 C for one subject; 38.5–38.9 C for one
subject; 38.0–38.4 for two subjects; 37.5–37.9 for two subjects
and below 37.5 C for the remaining six subjects. There was no
correlation between peak ex vivo IFNc ELISpot responses to antigen
85A and peak documented fever (Fig. 4A).
Peak ex vivo IFNc ELISpot responses to summed pools of antigen
85A peptides after 104 vaccinations with MVA85A in six clinical
R. Rowland et al. / Trials indening or pinkness around the injection site. 92% of local AEs were
mild and none were severe. The majority of subjects also reported
brief and mild viral symptoms 1 day after MVA85A vaccination,cinology 1 (2012) 27–35 33censed vaccines, the existing TB vaccine, live attenuated M. bovis
BCG and a live viral vaccine against Yellow Fever. These vaccines
were selected since they have similarities to MVA85A in terms of
Vacmycobacterial antigen (BCG) or live viral vector (Yellow Fever) and
are widely administered, including to healthy adults in temperate
countries. The transient local inflammation after MVA85A vaccina-
tion compares favourably to the injection site ulceration associated
with BCG vaccination. Although most trials did not report any
systemic AEs after BCG vaccination, it is a live mycobacterial vac-
cine with a risk of more serious systemic (disseminated) BCG infec-
tion. Disseminated BCG infection is unusual in immunocompetent
individuals, but the risk is much higher in the immunocompro-
mised, and HIV infection in infants is now a contraindication to
vaccination with BCG [30]. Yellow Fever vaccination induced ery-
thema, swelling and pain in most subjects when administered
intradermally and less frequently when subcutaneous (the usual
route). Comparable to MVA85A, Yellow Fever vaccination induces
a transient mild viral syndrome, with documented fever reported
in some subjects. Without a placebo control group, the frequencies
of non-specific systemic AEs that would be reported by the same
population in the same conditions in the absence of MVA85A
vaccination are not known. Randomised controlled trials (RCT) of
other vaccines have reported high rates of headache (19%), tired-
ness (18%) and any systemic AE (50%) in the placebo groups
[31,32]. Interestingly, the only clinical trial reporting any systemic
AEs after BCG vaccination was performed by our research group,
using the same methods as the MVA85A clinical trials, with a
7 days subject diary card and soliciting the same AEs [21]. In this
trial, headache, arthralgia, myalgia and feverishness were reported
by up to one third of subjects.
The frequency of local reactions seen after immunisation with
MVA85A, particularly erythema and swelling, reflects the intrader-
mal route of administration as well as the vaccine itself. Local
reactions are more frequent after intradermal compared to intra-
muscular or subcutaneous injections [29,31–35]. Safety and immu-
nogenicity of different routes of vaccination with MVA85A are
currently being evaluated. The systemic AEs reported after
MVA85A vaccination are more comparable to those reported after
other live viral-vectored vaccines than the existing TB vaccine,
BCG, suggesting the vector determines AEs to a greater extent than
the insert [33,36–41]. This is intuitive, since the viral vector
comprises the vast majority of the antigenic stimulus, and MVA
is chosen as a vector for antigen delivery precisely because of the
powerful innate immune response induced by the vector.
Protein-adjuvant vaccines are an alternative approach being
developed for new vaccines for TB and other infectious diseases.
These include the leading malaria vaccine RTS,S adjuvanted with
AS01B or AS02A; TB vaccine M72 in ASO2; malaria vaccine
AMA1-CA/ISA 720; and TB vaccine Hybrid 1 (Antigens 85B and
ESAT-6 in adjuvant IC31) [42–45]. Current data indicate that using
adjuvants will, like live viral vectors, induce local and systemic
reactions and that MVA85A is similar in tolerability to candidate
protein-adjuvant vaccines.
No correlations were found between peak immune responses
(1 week after vaccination) as measured by ex vivo IFNc ELISpot
and objective measures of systemic AEs (documented fever) or
local reactions (diameter of erythema). The immune assays were
evaluating the adaptive cellular immune response 7 days post-
vaccination. As both the onset of systemic AEs and the peak diam-
eter of erythema and swelling occur within the first 24–48 h after
vaccination, we speculate that the innate immune response is
largely responsible for the AE profile of MVA85A. If the effect of
sequential poxvirus vaccination on increasing local reaction size
is real, this may indicate that the adaptive immune response is also
involved. Pathways that have been shown to play important roles
in sensing MVA and coordinating the innate response include
34 R. Rowland et al. / Trials inTLR2-TLR6-MyD88, MDA-5-IPS-1 and NALP3 [46,47]. Work analys-
ing the innate immune response after MVA85A vaccination willenable analysis of the relationship between vaccine-induced innate
immunity and AE profile.
In summary, MVA85A is a well-tolerated TB vaccine candidate
that elicits a strong cellular immune response. Comparison to pub-
lished safety data for other vaccines suggests it has comparable
reactogenicity to other live viral vaccines, protein-adjuvant vac-
cines and intradermal vaccines. Local and systemic AEs reported
for MVA85A are not affected by increasing mycobacterial exposure
and do not correlate with the adaptive cellular immune response
to MVA85A. Further work to characterise the innate immune re-
sponse and evaluate its relationship with both AE profile and adap-
tive immune response is underway. It is essential that any new TB
vaccine being developed can be safely given to high-risk groups
and the safety evaluation of immunisation of HIV-infected subjects
is an important component of the ongoing clinical development of
MVA85A[6]. Current evaluation of the safety and immunogenicity
of MVA85A is also focusing on alternative routes of vaccination and
vaccine efficacy in target populations.
Clinicaltrials.gov identification numbers for the trials included
in this analysis: NCT00423566; NCT00465465; NCT00427453;
NCT00427830; NCT00653770; NCT00548444; NCT00456183;
NCT00653770.
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